For The Public (SE) For The Public (IT) For The Public (DE) For The Public (FI) For The Public (CZ) For The Public (GR)
Home
About Us
Contact us
Consortium Description
Management
Research Partners
Partner Institutions
Research Activities
Summary
Dissemination of Knowledge
News
Contact
Press Releases
Events
FP6 Facts
For The Public
(Multilingual Content)
Project
News And Views
FP6


Apotherapy: News

Search on This Topic:   
[ Go to Home | Select a New Topic ]


News News: Press Releases: December 15th, 2008
Posted by admin on Tuesday, January 20 @ 12:51:14 EET (1169 reads)

Press Release
15 December 2008

 

Researchers shed light on mechanisms behind the main cause of cancer deaths

Researchers at Barts and The London School of Medicine and Dentistry have shed light on a key mechanism behind the development of metastasis – the main cause of death associated with cancer.  The findings, published in Cancer Research, today (Monday, 15 December, 2008) could have potential in treating the spread of metastasis, and so reduce cancer deaths.

Metastasis is the ability of cancer cells to spread from a primary site, to form tumours at distant sites.  It is a complex process in which cell motility and invasion play a fundamental role. Essential to our understanding of how metastasis develops is identification of the molecules, and characterisation of the mechanisms that regulate cell motility.  Hitherto, these mechanisms have been poorly understood. Now, a team of researchers lead by Professor Marco Falasca at Barts and The London School of Medicine and Dentistry has shown not only that the enzyme phospholipase Cy1 (PLCy1) plays a crucial role in metastasis formation, but that down regulation of PLCy1 expression is able to revert metastasis progression.

The team investigated the role of PLCy1 in cell invasion and metastasis using different approaches to modulate its expression in highly invasive cancer cell lines.  Their results showed that PLCy1 is required for breast cancer cell invasion and activation of the protein Rac1.  They revealed a functional link between PLCy1 and Rac1 that provides insight into processes regulating cell invasion.

Professor Falasca explained: “Consistent with these data we detected an increase in PLCy1 expression in metastases compared to primary tumours in breast cancer patients. Therefore PLCy1 is critical for metastasis formation, and development and inhibition of this enzyme has a therapeutic potential in the treatment of metastasis dissemination.”

Ends-

‘Phospholipase Cy1 is Required for Metastasis Development and Progression’ is published in Cancer Research on Monday 15 December 2009.

The research was supported by The Association for International Cancer Research and by the European Commission FP6 program Apotherapy.

 

For further information contact:
Alex Fernandes
Communications Office
Queen Mary, University of London
Tel: 020 7882 7910
Email: a.fernandes@qmul.ac.uk

Notes to editors:
Barts and The London School of Medicine and Dentistry
Barts and The London School of Medicine and Dentistry – at Queen Mary, University of London - offers international levels of excellence in research and teaching while serving a population of unrivalled diversity amongst which cases of diabetes, hypertension, heart disease, TB, oral disease and cancers are prevalent, within east London and the wider Thames Gateway.  Through partnership with our linked trusts, notably Barts and The London NHS Trust, and our associated University Hospital trusts – Homerton, Newham, Whipps Cross and Queen’s – the School’s research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment.
At the heart of the School’s mission lies world class research, the result of a focused programme of recruitment of leading research groups from the UK and abroad and a £100 million investment in state-of-the-art facilities.  Research is focused on translational research, cancer, cardiology, clinical pharmacology, inflammation, infectious diseases, stem cells, dermatology, gastroenterology, haematology, diabetes, neuroscience, surgery and dentistry. 
The School is nationally and internationally recognised for research in these areas, reflected in the £40 million it attracts annually in research income. Its fundamental mission, with its partner NHS Trusts, and other partner organisations such as CRUK, is to ensure that that the best possible clinical service is underpinned by the very latest developments in scientific and clinical teaching, training and research.

Read More... | News: Press Releases

News News: Events: News: Events
Posted by admin on Tuesday, September 11 @ 13:10:04 EEST (3027 reads)

2nd Year Apotherapy Meeting: Istituto Mario Negri, Milan, Italy. (September 29th, 2008)

2nd Year Apotherapy Meeting: Istituto Mario Negri, Milan, Italy. (September 29th, 2008)



1st Year Apotherapy Meeting:
Hotel Megaron, Heraklion, Crete. 14-15 September 2007.

1st Year Apotherapy Meeting: Hotel Megaron, Heraklion, Crete. 14-15 September 2007.

CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
Read More... | News: Events

News News: Applications for Helsinki Biomedical Graduate
Posted by admin on Tuesday, September 11 @ 12:35:27 EEST (639 reads)

Doctoral Training Positions

Applications for Helsinki Biomedical Graduate School four-year international doctoral training positions for 2008-2011 are welcome between Sept. 12 - Sept. 26, 2007.

HBGS graduate students will participate in an excellent research training program including basic and advanced courses in biomedical research both on campus and internationally. Students work with supervisors from the outstanding Research Faculty affiliated with HBGS, and their progress is supported by a carefully selected thesis committee. The goal is to achieve a doctoral degree from the University of Helsinki Medical Faculty within the four-year period with the guidance of the thesis committee.

Read the Application ...
Read More... | News

News Content : News - Contact
Posted by admin on Monday, May 07 @ 16:53:36 EEST (1878 reads)

 
For media and press enquiries please contact :

Aristides Eliopoulos, PhD


E-mail apotherapyfp6@yahoo.gr
Phone +30.2810.39.4565 (Office)
+30.2810.39.4819 (Lab)
Fax +30.2810.39.4565
+30.2810.39.4530
Address Αristides Eliopoulos
Associate Professor of Molecular and Cellular Biology
Molecular and Cellular Biology Laboratory
Basic Sciences Division, Rm 2B-12
University of Crete Medical School
PO BOX 2208
71003 Heraklion Crete
Greece.
CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
Read More... | Content

News Content : Press Releases
Posted by admin on Monday, May 07 @ 16:49:57 EEST (2129 reads)

Apotherapy researchers shed light on mechanisms behind the main cause of cancer deaths.

(Read More ...)

(December 15th, 2008)
 

European Scientists Receive Funding From Sixth EU Framework Program to develop novel therapy for cancer.

(Read More ...)

(January 8th, 2007)
 
CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
Read More... | Content

Visitors:
Designed by: George Savakis for Virtual Medical Lab (Faculty of Medicine - Univercity of Crete)